Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 14Endometrial Neoplasms 11Ovarian Neoplasms 10Pancreatic Neoplasms 9Stomach Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Uterine Cervical Neoplasms 6Prostatic Neoplasms 6Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Lung Neoplasms 5Esophageal Neoplasms 5Neoplasms 4Breast Neoplasms, Male 4Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Gallbladder Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Neoplasms 2Urethral Neoplasms 2

Interventions

Hyperthermic Intraperitoneal Chemotherapy 28Paclitaxel 24Cisplatin 23Oxaliplatin 18Cytoreduction Surgical Procedures 17Carboplatin 17Fluorouracil 14Bevacizumab 10Mitomycin 9Leucovorin 9Doxorubicin 9Docetaxel 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Neoadjuvant Therapy 4Laparoscopy 4Blood Specimen Collection 4Albumin-Bound Paclitaxel 4sodium thiosulfate 3liposomal doxorubicin 3catumaxomab 3Taxes 3Drug Therapy 3Chemotherapy, Adjuvant 3tremelimumab 2relacorilant 2pembrolizumab 2olaparib 2nintedanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Trastuzumab × Gynecologic × Clear all
NCT01384253 2016-09-30

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Orano Med LLC

Phase 1 Completed
18 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡